A5085652006- COVID-19 and healthcare impacts
- Bladder and Urothelial Cancer Treatments
- COVID-19 Clinical Research Studies
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Multiple and Secondary Primary Cancers
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Healthcare cost, quality, practices
- Global Cancer Incidence and Screening
- Cancer survivorship and care
- Radiopharmaceutical Chemistry and Applications
- Geographic Information Systems Studies
- Testicular diseases and treatments
- Pancreatic and Hepatic Oncology Research
- Phagocytosis and Immune Regulation
- Social Media in Health Education
- Prostate Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Palliative Care and End-of-Life Issues
- Health Systems, Economic Evaluations, Quality of Life
- Distributed and Parallel Computing Systems
- Renal and related cancers
Stanford University
2016-2025
B.J. Medical College
2025
All India Institute of Medical Sciences Raipur
2024
Weatherford College
2024
The University of Texas MD Anderson Cancer Center
2023
The University of Texas Health Science Center at Houston
2023
Mays Cancer Center at UT Health San Antonio
2023
Stanford Medicine
2016-2022
Stanford Cancer Institute
2019-2021
Cancer Institute (WIA)
2021
PURPOSE To evaluate the safety, pharmacokinetics, and pharmacodynamics of Hu5F9-G4 (5F9), a humanized IgG4 antibody that targets CD47 to enable phagocytosis. PATIENTS AND METHODS Adult patients with solid tumors were treated in four cohorts: part A, determine priming dose; B, weekly maintenance C, study loading dose week 2; tumor biopsy cohort. RESULTS Sixty-two treated: 11 14 22 15 Part A used doses ranged from 0.1 3 mg/kg. On basis tolerability receptor occupancy studies showed 100%...
We have developed and previously reported on a therapeutic vaccination strategy for indolent B-cell lymphoma that combines local radiation to enhance tumor immunogenicity with the injection into of TLR9 agonist. As result, antitumor CD8(+) T cells are induced, systemic regression was documented. Because occurs in situ, there is no need manufacture vaccine product. now explored this second disease: mycosis fungoides (MF). treated 15 patients. Clinical responses were assessed at distant,...
Abstract Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments 30-day all-cause mortality factors associated treatment. Logistic regression multiple adjustments (e.g., comorbidities, status, baseline severity) was performed. Hydroxychloroquine any other drug increased versus treatment than hydroxychloroquine or untreated controls; this not present alone. Remdesivir had numerically reduced controls that...
Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer Network Investigate Therapeutic Experiences (UNITE) study, authors looked at experience with EV in patient subsets of interest which activity had not been well defined clinical trials.UNITE was retrospective study patients aUC treated recently agents. This initial analysis focused on EV. Patient data were abstracted from chart reviews...
In alignment with the International Council of Harmonization's strategic goals, a public-private consortium has developed structured template for planning and reporting on implementation real world evidence (RWE) studies safety effectiveness treatments. The serves as guiding tool designing conducting reproducible RWE studies; set clear expectations transparent communication methods; reduce misinterpretation prose that lacks specificity; allow reviewers to quickly orient find key information;...
Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality may be more common in patients with cancer treated immunotherapy (IO) immune system activation. Objective To determine the association of baseline immunosuppression and/or IO-based therapies severity cytokine cancer. Design, Setting, Participants This registry-based retrospective cohort study included 12 046 reported Cancer Consortium (CCC19) registry from March 2020 May 2022. The CCC19 is a centralized...
Authorization systems today are increasingly complex. They span domains of administration, rely on many different authentication sources, and manage permissions that can be as complex the system itself. Worse still, while there standards define mechanisms, address authorization less well defined tend to work only within homogeneous systems. This paper presents XACML, a standard access control language, one component distributed inter-operable framework. Several emerging which incorporate...
Crowd sourcing is based on a simple but powerful concept: Virtually anyone has the potential to plug in valuable information. The concept revolves around large groups of people or community handling tasks that have traditionally been associated with specialist small group experts. With advent smart devices, many mobile applications are already tapping into crowd report issues and traffic problems, more can be done. While most these work well for average user, it neglects information needs...
PURPOSE Patients with cancer face increasing difficulty securing access to timely, quality oncologic care. A virtual consultation program at a tertiary academic center could eliminate physical barriers while providing treatment recommendations that be executed locally. METHODS We evaluated an Online Second Opinions Program increase expert care via cloud-based platform through Included Health. This was open any patient globally who had local treating physician. Patient records were compiled...
107 Background: Patients (pts) with mCRPC can have different metastatic sites variable outcomes. Lu177-PVT is a novel treatment for but response and outcomes in the real world are still being defined. We hypothesized that pts lung liver metastases (mets) would worse (lower PSA shorter survival) than those without as advanced of disease spread. Methods: This retrospective cohort study analyzed who were treated at least one dose Lu177-PVT. PSA50, PSA90, overall survival assessed three...
867 Background: In trials testing enfortumab vedotin and pembrolizumab (EVP), prior treatment with immune checkpoint inhibitors (ICIs) was not permitted, resulting in a knowledge gap regarding efficacy of EVP patients (pts) previously treated ICIs. We hypothesized that would have pts ICI exposure. Methods: the retrospective UNITE study, we identified all to receiving EVP. The observed response rate (ORR) assessed evaluable who had imaging after ≥1 cycle following factors were evaluated...
632 Background: While Germ Cell Tumor (GCT) remain highly curable, up to 40% of patients (pts) with intermediate or poor risk advanced GCT will relapse. In the relapsed setting, high dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) may be pursued curative intent. To predict post-AHCT relapse, International Prognostic Factors Study Group created 5 categories incorporating 7 variables. The IPFSG score was prior popularization tandem/triplet transplants and...
Vaginal cancer is a rare yet aggressive cancer, with unmet need for novel therapeutics. In this case report, we present patient advanced stage, HPV-positive vaginal who demonstrated clinical, radiologic, and molecular response to combination treatment of antibody drug conjugate Enfortumab Vedotin (EV) Pembrolizumab. The had positive Nectin-4 staining on evaluation, raising the possibility future clinical application EV in squamous cell cancer.
Many grid usage scenarios depend on small, dynamic working groups for which the ability to establish transient collaboration with little or no intervention from resource administrators is a key requirement. The system developed, PRIMA, focuses issues of management and enforcement fine-grained privileges. Dynamic account creation leasing as well expressive mechanisms facilitate highly authorization policies least privilege access resources. PRIMA enable use finegrained rights, reduce...
Patients with metastatic cancer benefit from advance care planning (ACP) conversations. We aimed to improve ACP using a computer model select high-risk patients, shorter predicted survival, for conversations providers and lay coaches. Outcomes included documentation frequency end-of-life quality measures.In this study of improvement initiative, in four medical oncology clinics received Serious Illness Care Program training. Two (thoracic/genitourinary) participated an intervention, two...
Background There is limited experience regarding the safety and efficacy of checkpoint inhibitors (CPI) in patients with autoimmune disorders (AD) advanced urological cancers as they are generally excluded from clinical trials due to risk exacerbations. Methods This multicenter retrospective cohort analysis renal cell cancer (RCC) urothelial (UC) pre-existing AD treated CPI catalogued incidence exacerbations, new immune-related adverse events (irAEs) outcomes. Competing models estimated...